Inhibitex Investor Sues To Block $2.5B Bristol-Myers Deal
An Inhibitex Inc. shareholder launched a class action in Delaware state court on Wednesday challenging Bristol-Myers Squibb Co.'s $2.5 billion bid to acquire the biopharmaceutical company and its clinical-stage hepatitis C...To view the full article, register now.
Already a subscriber? Click here to view full article